p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma

David D. Wilson, Asal S. Rahimi, Drew K. Saylor, Edward B. Stelow, Mark J. Jameson, David C. Shonka, James F. Reibel, Paul A. Levine, Paul W. Read

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To investigate the prognostic significance of p16 in patients with hypopharyngeal squamous cell carcinoma (HPSCC) and to evaluate the relationship between p16 and human papillomavirus (HPV). Unlike in oropharyngeal SCC (OPSCC), the prognostic significance of p16 in HPSCC and its association with HPV is unclear. Design: Retrospective medical chart review. Setting: University tertiary referral center. Patients: A total of 27 patientswith HPSCC treated with definitive radiation therapy between 2002 and 2011 whose tissue was available for immunohistochemical analysis. Interventions: Twenty-two patients were treated with chemoradiation, and 5 with radiation alone. All tumor biopsy specimens were analyzed for p16 and, when sufficient tissue was available, for HPV DNA. Main Outcome Measures: Overall survival (OS), locoregional control (LRC), disease-free survival (DFS), and laryngoesophageal dysfunction-free survival (LEDFS) were analyzed according to p16 status. Results: Findings for p16 were positive in 9 tumors and negative in 18 tumors. Median follow-up was 29.3 months. There was no significant difference in OS, LRC, DFS, or LEDFS for patients with p16-positive vs p16-negative tumors. Only 1 of the 19 tumors tested for HPV was found to be HPV positive. When used as a test for HPV, p16 had a positive predictive value of 17%. Conclusions: In contrast to OPSCC, p16 expression in patients with HPSCC had a low positive predictive value for HPV and did not predict improved OS, LRC, DFS, or LEDFS. Thus, for HPSCC, p16 is not a prognostic biomarker. Caution must be taken when extrapolating the prognostic significance of p16 in patients with OPSCC to patients with head and neck SCC of other subsites.

Original languageEnglish (US)
Pages (from-to)556-561
Number of pages6
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume138
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Squamous Cell Carcinoma
Survival
Disease-Free Survival
Neoplasms
Tertiary Care Centers
Neck
Radiotherapy
Biomarkers
Head
Outcome Assessment (Health Care)
Radiation
Biopsy
DNA

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery

Cite this

Wilson, D. D., Rahimi, A. S., Saylor, D. K., Stelow, E. B., Jameson, M. J., Shonka, D. C., ... Read, P. W. (2012). p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma. Archives of Otolaryngology - Head and Neck Surgery, 138(6), 556-561. https://doi.org/10.1001/archoto.2012.950

p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma. / Wilson, David D.; Rahimi, Asal S.; Saylor, Drew K.; Stelow, Edward B.; Jameson, Mark J.; Shonka, David C.; Reibel, James F.; Levine, Paul A.; Read, Paul W.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 138, No. 6, 06.2012, p. 556-561.

Research output: Contribution to journalArticle

Wilson, DD, Rahimi, AS, Saylor, DK, Stelow, EB, Jameson, MJ, Shonka, DC, Reibel, JF, Levine, PA & Read, PW 2012, 'p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma', Archives of Otolaryngology - Head and Neck Surgery, vol. 138, no. 6, pp. 556-561. https://doi.org/10.1001/archoto.2012.950
Wilson, David D. ; Rahimi, Asal S. ; Saylor, Drew K. ; Stelow, Edward B. ; Jameson, Mark J. ; Shonka, David C. ; Reibel, James F. ; Levine, Paul A. ; Read, Paul W. / p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma. In: Archives of Otolaryngology - Head and Neck Surgery. 2012 ; Vol. 138, No. 6. pp. 556-561.
@article{5330794a5ed44b759d557591c551c7d6,
title = "p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma",
abstract = "Objective: To investigate the prognostic significance of p16 in patients with hypopharyngeal squamous cell carcinoma (HPSCC) and to evaluate the relationship between p16 and human papillomavirus (HPV). Unlike in oropharyngeal SCC (OPSCC), the prognostic significance of p16 in HPSCC and its association with HPV is unclear. Design: Retrospective medical chart review. Setting: University tertiary referral center. Patients: A total of 27 patientswith HPSCC treated with definitive radiation therapy between 2002 and 2011 whose tissue was available for immunohistochemical analysis. Interventions: Twenty-two patients were treated with chemoradiation, and 5 with radiation alone. All tumor biopsy specimens were analyzed for p16 and, when sufficient tissue was available, for HPV DNA. Main Outcome Measures: Overall survival (OS), locoregional control (LRC), disease-free survival (DFS), and laryngoesophageal dysfunction-free survival (LEDFS) were analyzed according to p16 status. Results: Findings for p16 were positive in 9 tumors and negative in 18 tumors. Median follow-up was 29.3 months. There was no significant difference in OS, LRC, DFS, or LEDFS for patients with p16-positive vs p16-negative tumors. Only 1 of the 19 tumors tested for HPV was found to be HPV positive. When used as a test for HPV, p16 had a positive predictive value of 17{\%}. Conclusions: In contrast to OPSCC, p16 expression in patients with HPSCC had a low positive predictive value for HPV and did not predict improved OS, LRC, DFS, or LEDFS. Thus, for HPSCC, p16 is not a prognostic biomarker. Caution must be taken when extrapolating the prognostic significance of p16 in patients with OPSCC to patients with head and neck SCC of other subsites.",
author = "Wilson, {David D.} and Rahimi, {Asal S.} and Saylor, {Drew K.} and Stelow, {Edward B.} and Jameson, {Mark J.} and Shonka, {David C.} and Reibel, {James F.} and Levine, {Paul A.} and Read, {Paul W.}",
year = "2012",
month = "6",
doi = "10.1001/archoto.2012.950",
language = "English (US)",
volume = "138",
pages = "556--561",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - p16 not a prognostic marker for hypopharyngeal squamous cell carcinoma

AU - Wilson, David D.

AU - Rahimi, Asal S.

AU - Saylor, Drew K.

AU - Stelow, Edward B.

AU - Jameson, Mark J.

AU - Shonka, David C.

AU - Reibel, James F.

AU - Levine, Paul A.

AU - Read, Paul W.

PY - 2012/6

Y1 - 2012/6

N2 - Objective: To investigate the prognostic significance of p16 in patients with hypopharyngeal squamous cell carcinoma (HPSCC) and to evaluate the relationship between p16 and human papillomavirus (HPV). Unlike in oropharyngeal SCC (OPSCC), the prognostic significance of p16 in HPSCC and its association with HPV is unclear. Design: Retrospective medical chart review. Setting: University tertiary referral center. Patients: A total of 27 patientswith HPSCC treated with definitive radiation therapy between 2002 and 2011 whose tissue was available for immunohistochemical analysis. Interventions: Twenty-two patients were treated with chemoradiation, and 5 with radiation alone. All tumor biopsy specimens were analyzed for p16 and, when sufficient tissue was available, for HPV DNA. Main Outcome Measures: Overall survival (OS), locoregional control (LRC), disease-free survival (DFS), and laryngoesophageal dysfunction-free survival (LEDFS) were analyzed according to p16 status. Results: Findings for p16 were positive in 9 tumors and negative in 18 tumors. Median follow-up was 29.3 months. There was no significant difference in OS, LRC, DFS, or LEDFS for patients with p16-positive vs p16-negative tumors. Only 1 of the 19 tumors tested for HPV was found to be HPV positive. When used as a test for HPV, p16 had a positive predictive value of 17%. Conclusions: In contrast to OPSCC, p16 expression in patients with HPSCC had a low positive predictive value for HPV and did not predict improved OS, LRC, DFS, or LEDFS. Thus, for HPSCC, p16 is not a prognostic biomarker. Caution must be taken when extrapolating the prognostic significance of p16 in patients with OPSCC to patients with head and neck SCC of other subsites.

AB - Objective: To investigate the prognostic significance of p16 in patients with hypopharyngeal squamous cell carcinoma (HPSCC) and to evaluate the relationship between p16 and human papillomavirus (HPV). Unlike in oropharyngeal SCC (OPSCC), the prognostic significance of p16 in HPSCC and its association with HPV is unclear. Design: Retrospective medical chart review. Setting: University tertiary referral center. Patients: A total of 27 patientswith HPSCC treated with definitive radiation therapy between 2002 and 2011 whose tissue was available for immunohistochemical analysis. Interventions: Twenty-two patients were treated with chemoradiation, and 5 with radiation alone. All tumor biopsy specimens were analyzed for p16 and, when sufficient tissue was available, for HPV DNA. Main Outcome Measures: Overall survival (OS), locoregional control (LRC), disease-free survival (DFS), and laryngoesophageal dysfunction-free survival (LEDFS) were analyzed according to p16 status. Results: Findings for p16 were positive in 9 tumors and negative in 18 tumors. Median follow-up was 29.3 months. There was no significant difference in OS, LRC, DFS, or LEDFS for patients with p16-positive vs p16-negative tumors. Only 1 of the 19 tumors tested for HPV was found to be HPV positive. When used as a test for HPV, p16 had a positive predictive value of 17%. Conclusions: In contrast to OPSCC, p16 expression in patients with HPSCC had a low positive predictive value for HPV and did not predict improved OS, LRC, DFS, or LEDFS. Thus, for HPSCC, p16 is not a prognostic biomarker. Caution must be taken when extrapolating the prognostic significance of p16 in patients with OPSCC to patients with head and neck SCC of other subsites.

UR - http://www.scopus.com/inward/record.url?scp=84863438739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863438739&partnerID=8YFLogxK

U2 - 10.1001/archoto.2012.950

DO - 10.1001/archoto.2012.950

M3 - Article

C2 - 22710507

AN - SCOPUS:84863438739

VL - 138

SP - 556

EP - 561

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 6

ER -